Iododerma biologically active composition

 

(57) Abstract:

The invention relates to iododerma biologically active compositions containing iodine and halides of nitrogenous bases of the formula I, where the values of the radicals a, b, C, R, X and m are specified in the claims. The composition is made in injectable form, in oral form, in the form of an ointment, an emulsion, in tincture form. The composition has a wide range of pharmaceutical activity. 10 C.p. f-crystals, 6 PL.

The invention relates to IDataReader biologically active compositions and can be used in the treatment of diseases of different etiology, in which the effective iodine preparations, as well as nutritional supplements.

Known pharmaceutical compositions containing iodine in combination with acetone and ethanol (France, C-CA N 2589061, A 61 K 33/18, 1987) hygienic purposes; salicylic acid, ethanol and alum (France, C-CA N 2614203, A 61 K 33/18, 1987) for the treatment of skin diseases; with surface-active substance RO-(C3H6O)m-(C2H4O)-CH2COOmwhere RO is the residue of the alcohol, antibacterial activity; with povidone and Polydextrose (U.S. patent N 4719106, A 61 K 31/79, 1988) bactericidal and is the antiseptic action containing less than one mole of iodine per mole of Quaternary ammonium salts, including Polyoxymethylene group [U.S. Pat. USA 3028301, 1962, C1 514-642; U.S. Pat. USA 3028427, 1962, C1 558-27; U.S. Pat. USA 2679533, 1951, C1 564-282].

The closest is the composition of the antiseptic action, containing less than 1 mol of iodine per 1 mol of the Quaternary ammonium salt, including fragments aminouksusnoy acid [U.S. Pat. USA 2860084, 1958, C1 424-10]. The disadvantage is its limited scope.

The technical result of the invention is to expand the Arsenal of drugs iodine with a wide range of pharmaceutical activity.

The technical result is achieved biologically active composition containing an effective amount as a source of active iodine mixture with a molar ratio of 0.2 to 4.1:1 iodine and halide (hydrogenogenic) the nitrogenous bases of the General formula I

< / BR>
where X Is Cl, Br, I; m = 1,2

A, B, C together with the nitrogen atom form a pyridine cycle

< / BR>
where R1, R2, R3, R4= hydrogen, alkyl, substituted alkyl, carbamid CONH2substituted hydrazide CONHNC(R'1)2substituted carbamic CON(R'1)2substituted carboxyl COOR'1where R'17), substituted alkyl (CH2)pPh, where p = 1 to 4;

- A, B, C together with the nitrogen atom form a benzimidazole cycle

< / BR>
where R1= hydrogen, lower alkyl (C1-C6), higher alkyl (C-7) and substituted alkyl, lower oxyalkyl (C1-C6), substituted carboxyl, substituted benzyl,

R2= hydrogen, lower alkyl (C1-C6), substituted alkyl,

R3= hydrogen, alkoxy,

a R takes values when m = 1 hydrogen, lower alkyl (C1-C6) substituted alkyl;

- A, B, C together with the nitrogen atom form a methenamine

< / BR>
a R takes values when m = 1 the lower alkyl (C1-C6), higher alkyl (C7), oxaalkyl, substituted benzyl;

A, B, C and R when m = 1 takes values hydrogen, lower alkyl (C1-C6), higher alkyl (> C7), substituted alkyl, benzyl, substituted benzyl, phenyl, substituted phenyl, the group - (CH2)pC6H5, (CH2)pOCOR1CH(Alk)COAr, (CH2)pCOOR2,

(CH2)pCONR3R4, (CH2)pOCHAr2where p = 1 to 4

R1= Alk, AlkOAr, CAlkAr2,

R2= lower alkyl (C1-C6), R3and R4= H, Alk, Ar, ArAlk,

and A, B, C, R take values when m = 2 in the2)pOCO(CH2)2(CH2)p- where p = 1 to 6;

- A, B, C together with the nitrogen atom form an imidazole cycle

< / BR>
where R1, R2, R3and R4= hydrogen, alkyl, substituted carboxyl,

and R takes values when m = 1 hydrogen, lower alkyl (C1-C6), higher alkyl ( C7);

- A, B, together with the nitrogen atom form a morpholine or thiazin

C takes on the value of hydrogen, lower alkyl (C1-C6)

R takes values when m = 1 alkyl, (CH2)pCOC6H5where p = 1 to 4;

- A, B, together with the nitrogen atom form a pieperazinove cycle

< / BR>
where R1= hydrogen, alkyl, galijasevic alkyl, substituted kynoselen,

C = hydrogen, alkyl, substituted alkyl when m = 1,

methylene when m = 2,

a R takes values alkyl when m = 1,

methylene when m = 2;

A and B together with the nitrogen atom form pyrazinoic cycle

< / BR>
where R1and R2= hydrogen, alkyl, substituted alkyl, substituted carboxyl,

accepts values hydrogen, alkyl.

R takes values when m = 1 alkyl, (CH2)pOCHPh2, COO(CH2)pN+(C2H5)2CH3I-where p = 1 to 6;

- A, B, C together with the nitrogen atom form the C together with the nitrogen atom form dihydroimidazole

< / BR>
where R1and R2together form a heterocyclic residue, R3= hydrogen, alkyl, Ph,

a R takes values when m = 1 hydrogen, alkyl;

- A, B, C together with the nitrogen atom form a thiazole

< / BR>
where R1and R2= hydrogen, lower alkyl, substituted alkyl,

and R takes values when m = 1 hydrogen, alkyl, substituted alkyl, pyrimidine;

- A, B, C together with the nitrogen atom form benzthiazole

< / BR>
where R1= Cl-N+Alk3(CH2)pOH, R2= hydrogen, N(CH3)pwhere p = 1 - 6,

a R takes values when m = 1 hydrogen, alkyl.

The composition exhibits antibacterial, Antiprotozoal, antifungal, antiviral, anti-inflammatory, antipyretic, antitumor, anti-tuberculosis, anti-ulcer, antioxidant, regenerative, antihelminthic activity.

To improve dispersion in ointments and emulsions, solubility in injectable and oral media (water, saline, ethanol composition may contain surface-active substances (surfactants) from a number of lanolin, polyetheramine, polyethylene glycol, twin, polyvinylpyrrolidone, carboxymethylcellulose, dextrin, pectin, dimethylsulfoxide, United Kingdom surfactant to 1:0.04 to 100.

The injectable form may contain a surfactant from a range of twin, polyvinylpyrrolidone, karboksimetilcelljuloza, dextrin, dimethylsulfoxide or a mixture of 1: 0.1 to 10 polyvinylpyrrolidone in an amount of 50 to 99 wt. %.

Oral forms (tablets, powders) may contain as surfactants polyvinylpyrrolidone, or twin, or carboximetilzellulozu, or dextrin, or pectin, or dimethylsulfoxide, or a mixture of polyvinylpyrrolidone and DMSO in a ratio of 1:0.1 to 10 and to improve the solubility may further comprise a sugar, for example lactose, or organic acid such as succinic, citric, aminouksusnoy in number, wt.%:

The total number of iodine and halide - 1,0 - 50,0

SURFACTANT - 2,0 - 50,0

Acid or sugar - Rest.

The oral form may also optionally contain to make sipacate sodium bicarbonate.

Ointments and emulsions can contain surfactants from a number of lanolin, twin, polyethylene glycol, polyvinylpyrrolidone in the amount of 0.5 to 12.0 wt.%, the total content of iodine and halide may be 0.5 to 12.0 wt.%, the basis of the rest.

The emulsion may further comprise an emulsifier, such as dimethylsulfoxide or tertiary alcohol (C7) in the amount of the Oia O. F. I, where R=the higher alkyl ( C7and iodine in the amount of 0.5 to 6.0 wt.%.

As ointment bases can be used, for example, petrolatum, or a mixture of 1: 0,5-3,0 weight parts of polyethylene glycol or polyethylenimine with water.

Outer tincture or drops can contain as surfactant dimethyl sulfoxide (DMSO) and optionally the solvent is ethanol or solvent in amount, wt.%:

The total number of halogen and iodine - 1,0 - 10,0

Ethanol - of 40.0 - 70.0

Water - the Rest

or

The total number of halogen and iodine - 1,0 - 10,0

DMSO AND 0.5 - 30,0

Ethanol - 40,0 - 50,0

Water - the Rest

The method of obtaining the composition is a mixture of components in the presence of a polar solvent, for example, from a number of dichloromethane, chlorate, chloroform, dichloroethane, acetonitrile, lower alcohols (C1-C3), water, dimethylsulfoxide and others, which are removed if necessary from the composition by distillation.

Examples of embodiment of the invention.

The composition is produced by mixing the components in a polar solvent: N-1, 16 - in 150 ml of chloroform, N 7 - in 180 ml of dichloromethane, N 8 in 100 ml of methanol, N 2, 10, 150 ml of ethanol, N 9 in 100 ml of acetonitrile with subsequent distillation, N oceny composition in the following ratio of components, wt.%:

1. Part 1 - 3,7

Twin - 1,0

Vaseline - Rest

(ointment)

2. Part 8 - 2,9

Lanolin - 0,7

A mixture of polyethylene glycol with water 1:1 - Rest

(ointment)

3. Part 11 - 2,5

A mixture of polyetheramine water - Rest

(ointment)

4. Part 23 - 1,5

Twin - 0,6

Dimethyl sulfoxide - 1,8

(emulsion)

5. Part 33 - 2,8

Lanolin - 1,0

Oktilovom alcohol - 4,0

A mixture of polyetheramine with water 1:0.5 to Rest

(emulsion)

6. Part 26 - 1,0

Dimethyl sulfoxide - 2,5

Vaseline - Rest

(emulsion)

7. Part 13 - 20,0

Polyvinylpyrrolidone (PVP) 80,0

8. Part 16 - 40,0

Carboxymethylcellulose - 60,0

9. Part 36 - 35,0

Dextrin - 65,0

10. Part 37 - 1,0

Twin - 99,0

song 7 - 10 - powder reddish-brown color, soluble in water;

11. Part 28 - 20,0

Dimethyl sulfoxide (DMSO) - 80,0

12. Part 32 - 10,0

A mixture of PVP and DMSO 1:1 to 90.0

13. The 6 - 5,0

DMSO - 1,0

Ethanol - 35,0

Water - the Rest

14. Part 8 - 1,0

Ethanol - 60,0

Water - the Rest

song 11 - 14 - solutions reddish-brown color;

15. 15 - 15,0

PVP - 30,0

Glucose - 30,0

NaHCO3- 10,0

Limona, 16 - powders, light brown, soluble in water.

In table. 1 shows used in the above examples iododerma components (compounds), including the halides of nitrogenous bases and iodine in a certain ratio.

In table. 1 shows the melting temperature (I.e. square) individual halides nitrogenous bases used in the manufacture of compositions. For nitrogen halides used in the form of ready medicinal forms, So pl. was not determined.

Other compositions containing as halide nitrogenous base compounds are given in table. 1.

Biological tests

Example 1. Antibacterial and antifungal activity

Study of antibacterial action proposed compositions listed in table. 1, was performed ten-fold serial dilutions in saline solution with successive planting in appropriate nutrient media. As the test microorganisms used the following microorganisms occupying different systematic position according to the determinant of Berga: gram-positive cocci - St. aureus - 209 R. Yu gram-negative Bacillus - E. coli - 88, spore-forming Bacillus - Cl the effectiveness of

Drugs using tracks 2, 10, 28, 33 at a dose of 10 mg/kg intraperitoneally reduced to normal body temperature of mice, increased by the action of pyrogenal, within 60 minutes after the injection.

Example 3. Regenerative activity

Study of the effect IDataReader compositions in the form of a 3% ointment on wound healing was carried out on white rats-males. After waxing the skin area in the back, two days later, inflicted two aseptic linear wounds on the depth of the underlying muscles. We observed three groups of animals. The experimental group applied the ointment at the rate of 100 mg/cm2twice a day, the second - methyluracil in a dose of 100 mg/kg (used as a standard of comparison, strengthens the processes of regeneration of wounds), the third group is the control and received saline 1 ml/100 g weight of the animal. Determination of the strength of the scar was performed on the fifth day after the incision method remotesite. The effort spent on reopening the wound, expressed in grams. The research results are summarized in table. 3.

Example 4. Definition topolitical compounds

In the experience of use 90 pigs with an average weight of 350 g, infected subcutaneously in the region of the right groin 0,Azania and spend 5 times a week for 60 days.

Compositions give Guinea pigs oral dose of 20 mg/kg per day, control the drug tubazide give the equivalent dose. Organs and tissues are subjected to pathological and bacteriological study. The results are presented in table. 4.

From table. 4 shows that the studied animals that received iododerma compositions vary considerably in weight control, weight increase on 48-78 g greater than that of the control. There are differences in the mass of bodies. All control animals tuberculous lesions localized predominantly in the introduction.

Animals treated iododerma songs or tubazide, morphologically tuberculous changes it is not revealed.

Given the toxicity of tubazide, LD50which is 363 mg/kg, therapeutic index of the compounds obtained more than an order of magnitude higher than the corresponding value for tubazide.

Example 5. Research antiulcer activity

Pharmacological studies have shown that iododerma compounds 2, 7, 15, 25, 38 have a high antiulcer activity.

Pharmacological data.

1. Pre-treatment compositions shows the B>50= 1-6 mg/kg orally.

2. Compounds prevent the development of stomach ulcers, induced by indomethacin (U50= 1,0 - 2,0 mg/kg oral), aspirin (U50= 1,0 - 3,0 mg/kg orally); aspirin + stress (U50= 8,0 - 20,0 mg/kg orally).

3. Compounds accelerate the healing of chronic gastric ulcers induced in rats with acetic acid at doses of 1 mg/kg per day in 73-92% of the animals.

4. The compositions inhibit caused by indomethacin gut ulcer.

Example 6. Research anthelminthic activity

In experiments, seminolipid white mice revealed that iodouridine composition in a single oral dose of 100 mg/kg is called a full (100%) exemption mice from hymenolepis. The minimum effective dose (MED) for the tested IDataReader compositions in gimenolepidoze mice ranges from 22 to 60 mg/kg In the group of mice treated fenasalom, all animals were released from seminolipid only with the drug orally in the dose of 100 mg/kg (see table. 5).

Example 7. Antiviral activity

Tested the efficacy of compounds 1, 7, 17, 25, 32 when parenteral introduction.

Mice weighing 7-10 g infected by a virus of simple German mice were divided into groups of 8-10 animals each. Groups of immunized animals substance was administered in doses of from 20 to 0.1 mg/kg for 7 days.

It was shown that the treated animals when parenteral injection in doses of 20.0-1.0 mg/kg of drugs were provided complete protection against lethal meningoencephalitis. At the same time in the control group animals death reached 80,95 of 8.8%, the obtained results are valid - P < 0,001 (PL.6). The introduction of drugs in doses of 1.0-0.1 mg/kg was accompanied by a significant reduction in mortality with 80,95 cent to 8.85 in untreated animals to 8.7 - 25,0 have treated, but the full protection of animals, as noted in the application of higher doses was not observed. The activity of the preparations was reached only with dose reduction to 0.01 mg/kg, but here the mortality rate of treated animals relative to controls did not reach statistical significance.

Example 8. Antitumor activity

When studying the activity of compounds 3, 11, 25, 32, 37 in experiments on solid tumors melanoma b-16 shows that in a wide range of doses from 1-300 mg/kg with the introduction of 20 times daily drugs cause 64-92% inhibition of tumor growth. The effect duration is 14 days. The optimal dose is 1 mg/kg daily for 20 days - criteria inhibition of tumor growth, projets a large range of doses (1-100 mg/kg) in the absence of toxic effects.

As the test showed, the proposed compositions have a broad spectrum of pharmacological activity: antibacterial, topolitical, antiulcer, anthelmintic, anti-virus, enterolithiasis, as well as low toxicity. The composition is stable during storage. It can be assumed that the proposed composition by analogy with iodine show anti-inflammatory, immunomoduliruushim, vitamin P and other activities. The halides of nitrogenous bases compositions 12-24, 25-31, 38, 39, used as medicines, retain their activity in the form of compositions with iodine. Unlike active I2the proposed compositions have low toxicity and prolonged action and can be used as drugs and preventive care, including food additives.

1. Biologically active composition containing iodine, characterized in that as a source of free iodine it contains an effective amount in a molar ratio of 0.2 to 4.1:1 iodine and halides of nitrogenous bases of General formula I

< / BR>
where X Is Cl, Br, I;

m =1,2; A, B, C together with the nitrogen atom form a pyridine cycle

< / BR>
where RCONHNC(R1')2substituted carbamic CON(R1')2substituted carboxyl COOR1'where R1' - C1-C6-alkyl;

R takes values when m=1 hydrogen, lower alkyl(C1-C6), higher alkyl (C7), substituted alkyl (CH2)pPh, where p=1 to 4;

-A, B, C together with the nitrogen atom form a benzimidazole cycle

< / BR>
where R1is hydrogen, lower alkyl (C1-C6), higher alkyl (C7) and substituted alkyl, lower oxyalkyl (C1-C6), substituted carboxyl, substituted benzyl;

R2is hydrogen, lower alkyl (C1-C6) substituted alkyl;

R3is hydrogen, alkoxyl;

R takes values when m=1 hydrogen, lower alkyl (C1-C6), and substituted alkyl,

< / BR>
-A, B, C together with the nitrogen atom form a methenamine;

R takes values when m=1 the lower alkyl (C1-C6), higher alkyl (C7), oxaalkyl, substituted benzyl;

-A, B, C and R when m =1 takes values hydrogen, lower alkyl (C1-C6), higher alkyl (>C7), substituted alkyl, benzyl, substituted benzyl, phenyl, substituted phenyl, the group - (CH2)pC6H5, (CH2)pOCOR1CH(AC)COAr, (CH2)pCOOR2,

(CH2)p>- lower alkyl (C1-C6);

R3and R4- H, l, Ar, ArAl,

A, B, C, R take values when m=2 hydrogen, lower alkyl, substituted benzyl, group (CH2)pNHCO-, (CH2)pOC6H4CH(l), (CH2)pOCO(CH2)p(CH2)p- where p=1 to 6;

< / BR>
-A, B, C together with the nitrogen atom form an imidazole cycle, where R1, R2, R3and R4is hydrogen, alkyl, substituted carboxyl;

R takes values when m=1 hydrogen, lower alkyl (C1-C6), higher alkyl (C7);

-A, B, together with the nitrogen atom form a morpholine or thiazin

C takes on the value of hydrogen, lower alkyl (C1-C6);

R takes values when m=1 alkyl, (CH2)pCOCbH5where p=1 to 4;

A and B together with the nitrogen atom form a pieperazinove cycle

< / BR>
where R1is hydrogen, alkyl, galijasevic alkyl, substituted kynoselen;

C is hydrogen, alkyl, substituted alkyl when m=1, methylene when m=2;

R takes values alkyl when m=1, methylene when m=2;

A and B together with the nitrogen atom form pyrazinoic cycle

< / BR>
where R1and R2is hydrogen, alkyl, substituted alkyl, substituted carboxyl;

C takes values hydrogen, alkyl;)2CH3I-, where p=12 - 6;

-A, B, C together with the nitrogen atom form Hinkley

< / BR>
where R1- OCOPh;

R takes values when m=1 hydrogen, lower alkyl;

-A, B, C together with the nitrogen atom form dihydroimidazole

< / BR>
where R1and R2together form a heterocyclic residue;

R3is hydrogen, alkyl, Ph;

R takes values when m=1 hydrogen, alkyl;

-A, B, C together with the nitrogen atom form a thiazole

< / BR>
where R1and R2is hydrogen, lower alkyl, substituted alkyl;

R takes values when m=1 hydrogen, alkyl, substituted alkyl, piperidin;

-A, B, C together with the nitrogen atom form benzthiazole

< / BR>
where R1-Cl-N+Alk3(CH2)pO, R2- hydrogen N (CH2)pwhere p=1 to 6;

R takes values when m=1 hydrogen, alkyl.

2. The composition according to p. 1, characterized in that it contains as halide iodide 1,3-diethylbenzamide.

3. The composition according to PP.1 and 2, characterized in that it additionally contains a surface-active substance (surfactant) selected from the range: lanolin, polyetheramine, polyethylene glycol, twin, polyvinylpyrrolidone, carboxymethylcellulose, dextrin, pectin, dimethylsulfoxide, compounds and surfactants 1:0.04 to 100 weight. h

4. The composition according to PP. 1 to 3, characterized in that it is made in injectable form and contains as a surfactant or polyvinylpyrrolidone, or twin, carboximetilzellulozu, or dextrin, or dimethylsulfoxide, or a mixture of polyvinylpyrrolidone with dimethylsulfoxide 1:0.1 to 10 in the following ratio, wt.%:

The total content of halogen and iodine - 1 - 50

SURFACTANT - 50 - 99

5. The composition according to PP.1 to 3, characterized in that it is made in oral form and as a surfactant contains or polyvinylpyrrolidone, or twin, or carboximetilzellulozu, or dextrin, or pectin, or dimethylsulfoxide, or a mixture of polyvinylpyrrolidone and DMSO in a ratio of 1:0.1 to 10, and optionally sugar, for example lactose, or an organic acid, selected from a number of amber, aminouksusnoy, lemon in the following ratio, wt.%:

The total content of halogen and iodine - 1,0 - 50,0

SURFACTANT - 2,0 - 5,0

Acid or sugar - Rest

6. The composition according to PP.1 to 3, characterized in that it is made in the form of ointments and contains as a surfactant or lanolin, or polyethylene glycol, or twin, or polyvinylpyrrolidone in the following ratio, wt.%:

The total content of halogen and O it is made in the form of an emulsion and contains as a surfactant or twin room, or lanolin, or polyethylene glycol, and optionally an emulsifier of a number of dimethylsulfoxide, higher alcohol (C7) in the following ratio, wt.%:

The total content of halogen and iodine - 0,5 - 10,0

SURFACTANT IS 0.5 TO 12.0

Emulsifier - 0,5 - 6,0

Emulsion base - Rest

8. The composition according to p. 1, characterized in that it is made in the form of an emulsion, contains halides of General formula I, where R is a higher alkyl (C7and iodine in a ratio of components, wt.%:

The total content of halogen and iodine - 0,5 - 6,0

Emulsion base - Rest

9. The composition according to p. 6, or 7, or 8, characterized in that ointment or emulsion as the basis or contains petrolatum, or a mixture of polyethylene glycol or polyetheramine with water in a ratio of 1 : 0,5 - 3,0.

10. The composition according to PP.1 to 3, characterized in that it is made in the form of tinctures and contains as a surfactant dimethyl sulfoxide (DMSO) and optionally the solvent is ethanol in the following ratio, wt.%:

The total content of halogen and iodine - 1,0 - 10,0

DMSO AND 0.5 - 30,0

Ethanol - 50 - 40

Water - the Rest

11. The composition according to PP.1 and 2, characterized in that it is made in the form of tinctures and includes the additional solvent is anal - of 40.0 - 70.0

Water - The Rest

 

Same patents:

The invention relates to a pharmaceutical dosage form for oral administration containing a proton pump inhibitor and one or more means of nonsteroidal anti-inflammatory therapy in the form of a metered dose of the drug, in which the proton pump inhibitor is protected intersolubility coating, means non-steroidal anti-inflammatory therapy, to a method for producing a dosage form and method for the treatment of side effects in the gastrointestinal tract as a result of treatment by means of a non-steroidal anti-inflammatory therapy

Antibacterial // 2157686
The invention relates to the field of medicine

The invention relates to new cyclopeptides formula cyclo-(pad-nGly-nAsp-nD-nE), where n, D, and E have the meanings indicated in the claims, and to pharmaceutical compositions based on them having inhibitory activity againstv3and/orv5-integrins and to a method for producing a pharmaceutical composition having inhibitory activity

Bactericidal togel // 2157206
The invention relates to medicine, namely to bactericidal hotovely

The invention relates to new derivatives of propiophenone having hypoglycemic activity, and method of production thereof
The invention relates to biotechnology, medicine, pharmacy and veterinary medicine, namely to medical forms medical immunobiological preparations (mibp) with bacteriophage as an active start
The invention relates to medicine, refers to the use of CGRP antagonists and/or for the preparation of cosmetic or pharmaceutical compositions, especially for topical application, for the treatment of ocular or palpebral of poonsuk (prurigo), ocular or palpebral pain and ocular or palpebral of dysesthesia

The invention relates to the field of medicine and is suitable for the treatment of cholecystitis, hepatitis, as well as urinary tract infections and gastroenteritis

The invention relates to the field of pharmaceutical industry and relates to a physiologically compatible emulsions containing hydrides perftoruglerodnykh esters

The invention relates to an external preparation for topical application, in particular to the outer local drug use, containing as activitiesthese substance 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or its pharmaceutically acceptable acid salt additive

The invention relates to the field of pharmaceutical industry and relates to emulsions of the type oil-in-water containing propofol and edentate

The invention relates to medicine, can be used in the production of pharmaceuticals and for the creation of tools for healing of purulent-necrotic wounds of different etiology

The invention relates to medicine, can be used in the production of pharmaceuticals and for the creation of funds - ascorbylpalmitate emulsion for the treatment of dermatoses
Propolis emulsion // 2145844
The invention relates to medicine, in particular to the emulsion on the basis of propolis

The invention relates to medicine and biotechnology and relates to a new method of obtaining spherical particles based on one or more active principles

The invention relates to medicine, namely to toxicology, and can be, in particular, used for the treatment of acute poisoning
The invention relates to medicine, in particular to composite medicines used for the treatment of skin diseases
Up!